A 28-day repeat dosing study in Göttingen minipigs concluded that proprietary formulations of ATx201 are well tolerated and leads to very low systemic exposure. BioAdvice, a leading GLP and GMP contract research organization located in Denmark, conducted the study. The outcome confirms previous studies suggestive of the favorable safety profile of ATx201.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.